61 related articles for article (PubMed ID: 15704140)
21. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
[TBL] [Abstract][Full Text] [Related]
22. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen.
Ghadersohi A; Sood AK
Clin Cancer Res; 2001 Sep; 7(9):2731-8. PubMed ID: 11555586
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
25. Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer.
Gort EH; Suijkerbuijk KP; Roothaan SM; Raman V; Vooijs M; van der Wall E; van Diest PJ
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3325-30. PubMed ID: 19064546
[TBL] [Abstract][Full Text] [Related]
26. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
[TBL] [Abstract][Full Text] [Related]
27. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
28. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
30. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
31. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D2 expression in familial and sporadic breast cancer.
Fischer H; Chen J; Skoog L; Lindblom A
Oncol Rep; 2002; 9(6):1157-61. PubMed ID: 12375011
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
34. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.
Kurebayashi J; Otsuki T; Kunisue H; Tanaka K; Yamamoto S; Sonoo H
Clin Cancer Res; 2000 Feb; 6(2):512-8. PubMed ID: 10690532
[TBL] [Abstract][Full Text] [Related]
35. [Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer].
Dahl E; Veeck J; An H; Wiesmann F; Klopocki E; Sauter G; Kristiansen G; Hartmann A; Knüchel R
Verh Dtsch Ges Pathol; 2005; 89():169-77. PubMed ID: 18035687
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells.
Zhang M; Wang Q; Yuan W; Yang S; Wang X; Yan JD; Du J; Yin J; Gao SY; Sun BC; Zhu TH
J Steroid Biochem Mol Biol; 2007; 105(1-5):91-7. PubMed ID: 17574840
[TBL] [Abstract][Full Text] [Related]
37. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
[TBL] [Abstract][Full Text] [Related]
38. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
[TBL] [Abstract][Full Text] [Related]
39. Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas.
Marmé A; Zimmermann HP; Moldenhauer G; Schorpp-Kistner M; Müller C; Keberlein O; Giersch A; Kretschmer J; Seib B; Spiess E; Hunziker A; Merchán F; Möller P; Hahn U; Kurek R; Marmé F; Bastert G; Wallwiener D; Ponstingl H
Int J Cancer; 2008 Nov; 123(9):2048-56. PubMed ID: 18709643
[TBL] [Abstract][Full Text] [Related]
40. Altered transcription control is responsible for the increased level of proliferation-associated P120 in rapidly growing breast carcinoma.
Fonagy A; Swiderski C; Freeman JW
Int J Cancer; 1995 Jan; 60(3):407-12. PubMed ID: 7829252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
